New Delhi, Sep 13 (IANS) Amid the global outbreak of Mpox, the World Health Organization (WHO) on Thursday announced prequalifying Bavarian Nordic’s vaccine — a first against the deadly monkeypox virus (MPXV).
Modified Vaccinia Ankara-Bavarian Nordic or MVA-BN is indicated for active immunisation against smallpox, Mpox, and related orthopoxvirus infections and disease in all adults 18 years of age and older.
The vaccine can be administered as a 2-dose injection given 4 weeks apart.
“Available data shows that a single-dose MVA-BN vaccine given before exposure has an estimated 76 per cent effectiveness in protecting people against Mpox, with the 2-dose schedule achieving an estimated 82 per cent effectiveness,” the WHO said in a statement.
“This first prequalification of a vaccine against Mpox is an important step in our fight against the disease, both in the context of the current outbreaks in Africa and in the future,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus.
Ghebreyesus stressed the need to “scale up in procurement, donations, and rollout to ensure equitable access to vaccines”.
In addition, other public health tools are also urgently needed “to prevent infections, stop transmission, and save lives”, he added.
The WHO prequalification comes even as the UN health body last month declared a global health emergency over its outbreak in Africa. The prequalification may facilitate timely and increased access, to contain transmission and help contain the outbreak.
The WHO’s assessment for prequalification is based on information submitted by Bavarian Nordic, and reviewed by the European Medicines Agency, the regulatory agency of record for this vaccine.
The MVA-BN is currently not licensed for persons under 18 years of age, but the WHO recommended its use “off-label” in infants, children, adolescents, and pregnant and people with weaker immune system in cases where the benefits of vaccination outweigh the potential risks.
MVA-BN is the only non-replicating Mpox vaccine approved in the US, Switzerland, and Singapore (marketed as JYNNEOS), Canada (marketed as IMVAMUNE), and the EU/EAA and UK (marketed as IMVANEX).
Meanwhile, more than 120 countries have confirmed over 103,000 cases of Mpox since the onset of the global outbreak in 2022.
In 2024 alone, there were 25,237 suspected and confirmed cases and 723 deaths from different outbreaks in 14 countries of the African Region.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
